Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT03198793
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT03198793
-
- Other papers using this trial's data
- Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03198793. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2018-10-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
- Acronym
- NEW-HOPE
- Condition
- Hypertension
- Intervention (Drug)
- QGC001
- Lead sponsor
- Quantum Genomics SA
Record details
- Record id
cardio:ct-nct03198793- Content hash
cf7e111752c5ddc068c67f892e946afe670ee80b714e37e70336c1802d9bd7ae